|
1）Strait KA, Stricklett PK, Chapman M, at al. Characterization of vasopressin-responsive collecting duct adenylyl cyclases in the mouse. Am J Physiol. 2010; 298: F859-67
|
|
|
|
|
2）Roos KP, Strait KA, Raphael KL, et al. Collecting duct-specific knockout of adenylyl cyclase type VI causes a urinary concentration defect in mice. Am J Physiol. 2012; 302: F78-84
|
|
|
|
|
|
3）Rieg T, Tang T, Murray F, et al. Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J Am Soc Nephrol. 2010; 21: 2059-68
|
|
|
|
|
4）Tamma G, Robben JH, Trimpert C, et al. Regulation of AQP2 localization by S256 and S261 phosphorylation and ubiquitination. Am J Physiol. 2011; 300: C636-46
|
|
|
|
|
|
5）Bohn AB, Norregaard R, Stodkilde L, et al. Treatment with the vascular disrupting agent Combretastatin is associated with impaired AQP2 trafficking and increased urine output. Am J Physiol. 2012; Epub ahead of print
|
|
|
|
|
|
6）Procino G, Mastrofrancesco L, Tamma G, et al. Calcium-sensing receptor and aquaporin-2 interplay in hypercalcuria-associated renal concentrating defect in humans. An in vivo and in vitro study. Plos One. 2012; 7: e33145
|
|
|
|
|
|
7）Li W, Zhang Y, Bouley R, et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol. 2011; 301: F309-18
|
|
|
|
|
|
8）Procino G, Barbieri C, Carmosino M, et al. Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. Pflugers Arch. 2011; 462: 753-66
|
|
|
|
|
|
9）Procino G, Barbieri C, Carmosino M, et al. Lovastatin-induced cholesterol depletion affects both apical sorting and endocytosis of aquaporin-2 in renal cells. Am J Physiol. 2010; 298: F266-78
|
|
|
|
|
|
10）Olesen ET, Rutzler MR, Moeller HB, et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A. 2011; 108: 12949-54
|
|
|
|
|
|
11）Bouley R, Lu HA, Nunes P, et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J Am Soc Nephrol. 2011; 22: 59-72
|
|
|
|
|
|
12）Boone M, Kortenoeven M, Robben JH, et al. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2010; 25: 48-54
|
|
|
|
|
|
13）Zhao H, Yao X, Wang TX, et al. PKCα regulates vasopressin-induced aquaporin-2 trafficking in mouse kidney collecting duct cells in vitro via altering microtubule assembly. Acta Pharmacol Sin. 2012; 33: 230-6
|
|
|
|
|
|
14）Kasono K, Saito T, Saito T, et al. Hypertonicity regulates the aquaporin-2 promoter independently of arginine vasopressin. Nephrol Dial Transplant. 2005; 20: 509-15
|
|
|
|
|
|
15）Saito T, Saito T, Kasono K, et al. Hypotonicity reduces the activity of murine aquaporin-2 promoter by dibutyryl cAMP. Exp Physiol. 2008; 93: 1147-56
|
|
|
|
|
|
16）Kortenoeven ML, van den Brand M, Wetzels JF, et al. Hypotonicity-induced reduction of aquaporin-2 transcription in mpkCCD cells is independent of the tonicity responsive element, vasopressin, and cAMP. J Biol Chem. 2011; 286: 13002-10
|
|
|
|
|
|
17）Wang W, Li C, Summer S, et al. Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration. Am J Physiol. 2010; 299: F577-84
|
|
|
|
|
|
18）Stegbauer J, Gurley SB, Sparks MA, et al. AT1 receptors in the collecting duct directly modulate the concentration of urine. J Am Soc Nephrol. 2011; 22: 2237-46
|
|
|
|
|
|
19）Li C, Wang W, Rivard CJ, et al. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am J Physiol. 2011; 300: F1255-61
|
|
|
|
|
|
20）Kanno K, Sasaki S, Ishikawa S, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med. 1995; 332: 1540-5
|
|
|
|
|
|
21）Saito T, Ishikawa S, Sasaki S, et al. Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insupidus. J Clin Endocrinol Metab. 1997; 82: 1823-7
|
|
|
|
|
|
22）Sasaki S, Ohtomo Y, Mori T, et al. Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method. Clin Exp Nephrol. 2012; 16: 406-10
|
|
|
|
|
23）Graffe CC, Bech JN, Lauridsen TG, et al. Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. Am J Physiol. 2012; 302: F917-27
|
|
|
|
|
|
24）Rocchetti MT, Tamma G, Lasorsa D, et al. Altered urinary excretion of aquaporin 2 in IgA nephropathy. Eur J Endocrinol. 2011; 165: 657-64
|
|
|
|
|
|
25）Graffe CC, Bech JN, Pedersen EB. Effect of high and low sodium intake on urinary aquaporin-2 excretion in healthy humans. Am J Physiol. 2012; 302: F264-75
|
|
|
|
|
|
26）Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-112
|
|
|
|
|
|
27）Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011; 164: 725-32
|
|
|
|
|
|
28）Cardenas A, Gines P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012; 56: 571-8
|
|
|
|
|
|
29）Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 214: 705-12
|
|
|
|
|
|
30）Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA. 2007; 297: 1319-31
|
|
|
|
|
|
31）Pang PS, Gheorghiade M, Dihu J, et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J. 2011; 161: 1067-72
|
|
|
|
|
|
32）Blair JE, Pang PS, Schrier RW, et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011; 32: 2563-72
|
|
|
|
|